APHINITY

BIG 4-11

APHINITY logo

Share This Post

A randomised, multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer.

APHINITY has been testing whether adding a drug called pertuzumab to the standard adjuvant treatment (trastuzumab and chemotherapy) in patients with operable HER2-positive (HER+) primary breast cancer improves the outcome of patients with the disease.

Previous studies have shown that the use of the drug trastuzumab (Herceptin®) improves the chances of disease-free survival of patients with HER2+ breast cancer. This drug has been approved and licensed. It is now the standard of care to give trastuzumab along with chemotherapy after surgery for patients with HER2+ breast cancer.

The study’s first results, presented at American Society of Clinical Oncology Annual Meeting 2017 and published in the New England Journal of Medicine that same year, found that the new dual anti-HER2 therapy regimen reduced the risk of breast cancer recurrence or death by 19% compared to trastuzumab and chemotherapy alone. At three years, 94,1% of patients treated with pertuzumab in combination with trastuzumab and chemotherapy did not see a breast cancer recurrence, compared to 93,2% of patients treated with trastuzumab and chemotherapy alone.

The first results of the APHINITY trial therefore showed a modest benefit from adding pertuzumab to trastuzumab, in itself an important step in advancing cancer care for patients – especially for women with the highest risk – those with node-positive and hormone-receptor negative breast cancer.

The updated results, presented at the San Antonio Breast Cancer Symposium 2019 and published in the Journal of Clinical Oncology in 2021, showed that, after six years of follow-up, the greatest benefit remained in patients at high risk of recurrence, such as those with lymph node-positive disease, but regardless of hormone receptor status. Although fewer deaths were seen among the patients who received treatment with pertuzumab, the data are still immature and have not shown definitive improvement in overall survival, which will be reviewed again at a next interim analysis.

Patients enrolled in APHINITY were randomly assigned to one of the following treatments:  
– Chemotherapy and trastuzumab combined with pertuzumab,
 OR
– Chemotherapy and trastuzumab with placebo.

The patients were treated for one year. The study will compare results between the two treatments, looking at the invasive disease free survival, overall survival, and safety.

During the trial, samples (blood and tumour tissue) have been collected from all participating patients and stored in the study biorepository for future research.

This will help us identify biomarkers, which can help to:
– predict response or toxicity (side effects) of the dual anti-HER treatment
– better understand the biology of HER2+ tumours
– develop and validate diagnostic tests

Patients aged 18 and older, with known hormone receptor status (estrogen receptor [ER] and progesterone receptor [PgR]), and confirmed HER2+ breast cancer. This means that the cells have been tested positive for a protein called HER2.
A total of 4,805 patients were recruited.

This study is conducted by BIG Headquarters, in collaboration with the Institut Jules Bordet – Clinical Trials Support Unit (IJB/CTSU) and Frontier Science Scotland (FSS), which serve respectively as independent data and statistical centres.

Pharmaceutical partner: Roche

24 research groups from the BIG network are participating in this trial.

The last patient was recruited in August 2013.
All patients completed their one year of treatment and will be followed up for 10 years after the date the last patient was enrolled.

The trial is being conducted in 42 countries, with a total of 563 hospitals worldwide.  
290 of the participating hospitals are affiliated with the 24 participating BIG groups.

The trial is fully funded by Roche (sponsor). It was designed and conducted following BIG’s Principles of Research Conduct.

More To Explore

PANACEA

Panacea BIG 4-13 PANACEA stands for anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab

Read More

DECRESCENDO

DECRESCENDO BIG 19-02 De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade Share

Read More